Cryptococcus neoformans is a frequent opportunistic pathogen in humans, particularly in patients with defects in cell-mediated immunity (10, 14) . C. neoformans is an important pathogen in patients with acquired immune deficiency syndrome, in whom there is a profound deficiency of T helper lymphocytes (14) . Although the mechanism of protection against C. neoformans in humans is incompletely understood, the increased incidence in patients with defects in cell-mediated immunity suggests that functional T cells are important in protection (22) . The present study was performed to develop a model of cryptococcal infection in the setting of impaired T-cell function.
Cyclosporin A (CsA) is a cyclic endecapeptide originally derived as a crude extract of two strains of Fungi Imperfecti, Cylindrocarpum lucidum Booth and Tolypocladium inflatum Gams. Although initially discovered while attempting to identify new antifungal agents, CsA is now used widely as a potent immunosuppressive agent, particularly in human allograft transplantation (9) .
The mechanism of immunosuppression induced by CsA has been extensively studied in animals and humans. CsAmediated T-cell immunosuppression is believed to be due to the decreased release of interleukin 2 from stimulated T lymphocytes, resulting in a failure to develop a specific immune response (8, 12) . B lymphocytes are affected only secondary to failure of the T helper cells (4) , and the effector activity of macrophages has been shown to be normal (27) . We treated mice with daily injections of CsA and inoculated them with pathogenic encapsulated C. neoformans to study the pathogenesis of C. neoformans infections in a murine model of T-cell dysfunction. To our surprise, CsA treatment prolonged survival indefinitely. Furthermore, pulmonary clearance of C. neoformans was enhanced in CsA-treated mice, and the enhanced clearance in vivo correlated with a direct effect of CsA on C. neoformans growth in vitro.
MATERIALS AND METHODS Animals. Adult male C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, Maine) at 6 to 8 weeks of age. They were housed in a sterile filter hood and monitored for mycoplasma and Sendai virus infections. All animals received mouse chow and sterile water ad libitum.
CsA. CsA (Sandimmune IV) was donated by Sandoz Inc. (East Hanover, N.J.). CsA was diluted with normal saline (final concentration, 2.5 or 5 mg/ml). A control solution was prepared with the carrier for CsA, 3.25 ml of Cremaphor-EL (Cr-E; Sigma Chemical Co., St. Louis, Mo.), plus 1.6 ml of ethanol, and diluted to correspond to the carrier concentration in CsA with normal saline for subcutaneous administration.
CsA assay. Whole blood (0.5 to 1.0 ml) was obtained from the retroorbital plexus of mice in heparinized tubes (75 p,l of a 1:10,000 solution). CsA was extracted and quantified by high-performance liquid chromatography (18) . Briefly, 0.25 ml of whole mouse blood was combined with 0.75 ml of pooled human blood. To each tube, 2 ml of internal standard (cyclosporin D; 250 ng/ml in acetyl nitrite-methanol [9:1]; Sandoz Inc.) was added. Specimens were then vortexed and centrifuged, and the supernatant was combined with 1 ml of H20. Samples were then bound to a 6-ml, reverse-phase column (C18 column; Analytichem, Harbor City, Calif.) and washed with 70% methanol-1% acetone in hexane. Cyclosporin was eluted from the column with ethyl acetate in isopropanol (3:1). Specimens were further purified on a 3-ml silica column (SI column; Analytichem), dried, and reconstituted with acetyl nitrite and methanol in H20 (19) . Briefly, animals were anesthetized with pentobarbital. The trachea was exposed, and the animal was intubated with a blunt-tipped, 20-gauge steel needle. A plastic cannula (PE-10 tubing; Clay Adams, Parsippany, N.J.) was inserted through the steel needle 2.8 cm from the teeth into the trachea. A 5-,ul slurry containing C. neoformans was deposited by using 100 ,ul of air. Immediately after inoculation, two or three mice from each treatment group were sacrificed. The lungs were harvested, and the number of CFU was determined as described above. These CFU were considered the deposition by i. (Fig. 3) . The Effect of CsA on survival in mice receiving C. neoformans i.t. We examined the effect of CsA on survival following i.t. inoculation of C. neoformans. Mice received CsA (50 mg/kg per day) or a control solution beginning on the day prior to i.t. inoculation with C. neoformans 145A (104 CFU). The first animal in the control group died 40 days after inoculation, and the mean survival time was 51.5 ± 1.1 days (Fig. 4) . All animals in the control group were dead by day 55. This survival was similar to that of untreated animals inoculated i.t. with 104 CFU in preliminary experiments (data not shown). CFU at death in control mice revealed dissemination from the lung with prominent central nervous system infection (the CFU [log1o] was as follows in: lung, 7.13 + 0.14; spleen, 4.43 ± 0.15; kidney, 4.28 ± 0.38; liver, 4.89 + 0.27; and brain, 6.96 ± 0.05). All CsA-treated animals survived until the experiment was terminated on day 69, 14 days after the last death in the control group. The CFU in a representative mouse receiving CsA, in CFU (log1o), was as follows in: lung, 2.6; spleen, 0.9; kidney, 2.3; liver, 2.0; brain, 1.6 .
Effect of CsA on mitogen-induced lymphoproliferation. Lastly, we determined the effect of chronic CsA treattnent on the response of splenocytes to the T-cell mitogen concanavalin A. There was a significant reduction in the response (3 x 105/well) to 2 ,ug of concanavalin A per ml was compared with that of splenocytes from controls. The responses of splenocytes from all treated animals were significantly different from those of control splenocytes. Symbols: *, P < 0.05; **, P < 0.001.
to concanavalin A of splenocytes from CsA-treated mice as compared with those from controls (Fig. 5 ).
DISCUSSION
Results of this study indicate that CsA enhances survival following both i.v. and i.t. inoculation of C. neoformans. Furthermore, CsA enhances the clearance of C. neoformans from the lung following i.t. inoculation. The mechanism of enhanced survival and clearance relates at least in part to the direct inhibition of cryptococcal growth as shown by in vitro testing.
C. neoformans 145A was administered both i.v. and i.t. during this study. Intravenous inoculation of organisms has been widely used to study the pathogenesis of cryptococcal infections and may represent a model of fungemia. Following i.v. inoculation, organisms were found in lung, liver, kidney, spleen, and brain. A prominent central nervous system infection was present at death. However, cryptococcosis is likely acquired by the pulmonary route (11, 16) . Therefore, i.t. inoculations were used predominantly in these studies. The inoculum size was chosen because in control animals it was associated with widespread dissemination and 100% mortality. Lower inoculum sizes did not uniformly result in dissemination and death. Control animals inoculated i.t. also developed widespread dissemination, although the course of the infection was more prolonged than in the i.v. model. A prominent central nervous system infection was present at death in animals inoculated i.t., as well as those inoculated i.v.
These data demonstrate an anticryptococcal effect of CsA. However, CsA administration has been previously shown to be immunosuppressive. The doses of CsA used in these experiments have been shown to cause T-cell dysfunction in previous studies. Prolonged skin allograft survival and depressed delayed hypersensitivity was demonstrated following administration of 70 and 300 mg of CsA per kg per day, respectively (3, 4 strated that all CsA treatment protocols diminished the response of spleen cells to the mitogen concanavalin A following 7 days of CsA treatment. This strongly suggests that the levels of CsA in our experimental animals would have been sufficient to prevent the development of specific immune responses. These data are similar to those given in a previous report (21) , in which it was shown that CsA diminished the response of rabbit peripheral blood lymphocytes to concanavalin A. Thus, since growth of C. neoformans is likely enhanced by the immunosuppressive effect of CsA, the apparent antifungal effect of CsA is actually less than would be observed if immunosuppression were not also operative in the experimental animals.
Nevertheless, levels of CsA in serum are variable in mice, and it has been proposed (1) that levels in serum be measured in experimental systems when CsA is used. The preparation of CsA we used (Sandimmune IV) has not been used in s.c. administration in mice. Injections of 50 to 75 mg of CsA per kg per day by the s.c. route yielded levels within the range that produced immunosuppression in in vitro experiments with murine lymphoid cells (8, 15) . Recently, it has been shown that subcutaneous administration of CsA with the equivalent of 25 mg/kg (in an average 25-g mouse) correlated with a CsA level in serum at 24 h of 0.33 ,ug/ml (23) . This level of CsA was shown to decrease the mortality and neurologic signs in a murine model of experimental allergic encephalomyelitis, and to decrease the production of lymphokine-derived chemotactic factor (23) . Despite the likelihood that profound immunosuppression was induced in our mice by CsA, treated animals cleared C. neoformans 145A effectively and survived. In contrast, in control animals C. neoformans grew at a rate similar to that of untreated mice in previous experiments, and all mice rapidly succumbed to cryptococcal infection.
The level of CsA in blood in human immunosuppressive therapy ranges between 0.1 and 0.3 ,ug/ml and is 10-fold less than that achieved in murine immunosuppressive therapy when mice receive 50 to 75 mg of CsA per kg per day. In the i.t. inoculation experiment in which 20 mg of CsA per kg per day was used, levels in blood were 0.3 ,g/ml, which is in the range of that in transplant patients (7) and the same as that which produces immunosuppression in a murine model of experimental allergic encephalitis. In mice that received 20 mg of CsA per kg per day, we demonstrated effective clearance of three strains of C. neoformans from the lungs as compared with that in mice that received a control solution. Levels of CsA in blood were used to select the concentration of CsA in an in vitro assay. Results of the in vitro experiments demonstrated that concentrations of CsA of 0.1 pLg/ml were also effective in inhibiting the growth of these same three strains.
The susceptibility of other fungal organisms to CsA has been demonstrated in vitro for Aspergillus candidus, Saccharomyces cerevisiae, and Candida albicans (20) . Susceptibility to CsA has also been documented in vitro and in vivo with Leishmania major and Leishmania tropica (2, 25) . In vivo susceptibility to CsA has been shown with Schistosoma mansoni (5), Coccidioides immitis (13), Plasmodium sp. (26) , Dipetalonema vitae (6), and Toxoplasma gondii (17) . Of particular relevance to our studies, CsA has not been shown to affect the growth of C. neoformans either in vitro or in vivo in two other studies (20, 21) .
The failure of the in vitro sensitivity of C. neoformans to CsA to be demonstrated in other studies might reflect the assay system. The in vitro susceptibility testing of CsA in our studies was performed by using a commercially available preparation of CsA in Cr-E, which allowed for the more uniform dispersion of CsA. Broth rather than agar was used, and the medium was constantly agitated on an orbital shaker to promote aeration and uniform distribution. By using this assay system, the susceptibility demonstrated in vitro correlated with the enhanced clearance and survival shown in vivo.
Our results differed from those reported previously (21) in a model of C. neoformans meningitis in rabbits immunosuppressed with CsA. C. neoformans was administered directly into the intrathecal space, while CsA (30 mg per rabbit) was administered i.v. Cryptococcus was cleared less effectively in immunosuppressed rabbits. CsA was not detected in cerebrospinal fluid with an assay which could detect 0.005 ,ug of CsA per ml. This low level of CsA in cerebrospinal fluid may explain the lack of apparent susceptibility of the organism to CsA in this model. Alternatively, the differences in route of infection and in doses of CsA used may account for the differences in results between these two studies.
In summary, CsA administration prolonged the survival of mice inoculated with C. neoformans either i.v. or i.t. The enhanced survival was associated with a reduced burden of C. neoformans in lung, spleen, liver, kidney, and brain. Furthermore, following i.t. inoculation of the organism, CsA administration markedly enhanced the clearance of C. neoformans from the lungs. Finally, the enhanced survival and clearance correlated with inhibition of growth of C. neoformans by CsA in vitro. The susceptibility of C. neoformans was documented at levels in serum that are in the therapeutic range for the human transplant population. Further work must be done to define the sensitivity of C. neoformans in mice treated after an established infection, particularly when the central nervous system is infected. While these results would have to be extended to studies in humans, these data suggest that patients who now receive CsA may be fortuitously protected against certain infections with C. neoformans. Furthermore, it is possible that CsA might be modified to be less immunosuppressive and thus useful in the treatment of patients with cryptococcal infections.
